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ABSTRACT
Introduction: Medication adherence is fundamental to
achieving optimal patient outcomes. Reporting
research on medication adherence suffers from some
issues—including conceptualisation, measurement and
data analysis—that thwart its advancement. Using the
ABC taxonomy for medication adherence as the
conceptual basis, a steering committee of members of
the European Society for Patient Adherence,
COMpliance, and Persistence (ESPACOMP) launched
an initiative to develop ESPACOMP Medication
Adherence Reporting Guidelines (EMERGE). This paper
is a protocol for a Delphi study that aims to build
consensus among a group of topic experts regarding
an item list that will support developing EMERGE.
Methods and analysis: This study uses a reactive-
Delphi design where a group of topic experts will be
asked to rate the relevance and clarity of an initial list
of items, in addition to suggesting further items and/or
modifications of the initial items. The initial item list,
generated by the EMERGE steering committee through
a structured process, consists of 26 items distributed
in 2 sections: 4 items representing the taxonomy-
based minimum reporting criteria, and 22 items
organised according to the common reporting
sections. A purposive sample of experts will be
selected from relevant disciplines and diverse
geographical locations. Consensus will be achieved
through predefined decision rules to keep, delete or
modify the items. An iterative process of online survey
rounds will be carried out until consensus is reached.
Ethics and dissemination: An ethics approval was
not required for the study according to the Swiss
federal act on research involving human beings. The
participating experts will be asked to give an informed
consent. The results of this Delphi study will feed
into EMERGE, which will be disseminated through
peer-reviewed publications and presentations at
conferences. Additionally, the steering committee will
encourage their endorsement by registering the
guidelines at the Enhancing the QUAlity and
Transparency Of health Research (EQUATOR) network
and other relevant organisations.
INTRODUCTION
Reporting research on medication adher-
ence is suboptimal. Confusion prevails
regarding the conceptual underpinning,
adequate measurement and analysis of medi-
cation adherence data, hindering scientiﬁc
progress in this ﬁeld.1–3 Guidelines on the
reporting of health research aim at enhan-
cing publication quality and may focus on
speciﬁc study designs, research areas or sec-
tions of a report. Examples of such guide-
lines can be found on the website of the
Enhancing the QUAlity and Transparency
Of health Research (EQUATOR) network
(http://www.equator-network.org), and in-
clude STROBE4 (for observational studies in
epidemiology), CONSORT5 (for trials) and
TIDieR6 (for description and replication of
interventions) guidelines. The introduction
of such guidelines and their endorsement
by professional societies and journals has
proven to be helpful in enhancing the trans-
parency and accuracy of health research
reporting.7 8
There are existing published guidelines
and recommendations focusing on medica-
tion adherence research.1 9–12 However,
these guidelines overlap considerably with
those developed for general clinical research
and are thus not particularly speciﬁc for medi-
cation adherence research.9 10 Additionally,
they do not build on a clear conceptualisation
Strengths and limitations of this study
▪ Incorporates the input of many topic experts
across various disciplines and geographical
areas.
▪ Preserves subject anonymity and reduces the
effect of dominant individuals.
▪ Uses statistical analysis techniques to reduce the
potential of group pressure for conformity.
▪ Requires large blocks of time to administer
several survey rounds and consolidate their
output.
▪ Has potential to mould opinions based on the
received aggregate feedback.
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of medication adherence,1 9 10 12 and focus on study
design rather than reporting.1 11 12 Considering the short-
comings of the existing guidelines and the aforemen-
tioned deﬁcits in the quality of medication adherence
research, this ﬁeld would beneﬁt from speciﬁc reporting
guidelines to boost the quality of reporting medication
adherence research.
A steering committee of members of the European
Society for Patient Adherence, COMpliance, and
Persistence (ESPACOMP, http://www.espacomp.eu)
launched an initiative to develop ESPACOMP Medication
Adherence Reporting Guidelines (EMERGE) that will
tackle the aforementioned shortcomings in the following
manner. Considering the conceptualisation of medica-
tion adherence, the anticipated guidelines will build on
the ABC taxonomy for medication adherence.13 This tax-
onomy deﬁnes medication adherence as ‘the process by
which patients take their medications as prescribed’. It
divides this process into three inter-related phases: (1)
initiation; (2) implementation and (3) persistence, each
demanding a clear operational deﬁnition and appropri-
ate measurement and data analysis. Hence, setting this
conceptualisation as a standard for reporting medication
adherence research is anticipated to remove the ambigu-
ity surrounding medication adherence as a concept.
Additionally, designing the guidelines attentively to avoid
overlapping with the existing guidelines for general clin-
ical research has a twofold beneﬁt. First, it will steer clear
of redundancy and, thus, any confusion that might arise
accordingly. Second, it will allow the new guidelines to be
applied to the different study designs and used in parallel
with the general guidelines available for the correspond-
ing study design. Finally, developing the guidelines as
reporting guidelines will help both the authors in ﬁgur-
ing out the important elements to be reported about
their research and the reviewers in critically appraising
the quality of the studies.
Developing reporting guidelines, however, requires
input by experts from various scientiﬁc backgrounds and
needs to be relevant across geographical regions. This is
particularly applicable in the context of medication
adherence, which is a multidisciplinary science ranging
from behavioural sciences through statistics and clinical
medicine to economics. Delphi methodology, as a
means for consensus building,14 enables integration of
input from a wide variety of experts. It achieves consen-
sus through an iterative process of survey rounds, provid-
ing an opportunity for its participants to revise their
input in subsequent rounds based on collective group
feedback from previous rounds. This method enables
the neutral and efﬁcient integration of feedback from
different experts, is suggested as 1 of the 18 steps put
forward by the EQUATOR network in their guidance on
developing health research reporting guidelines15 and
has been used in developing many similar
guidelines.16 17
This approach has many beneﬁts.18–20 First, the itera-
tive nature of the study and the feedback process allows
the participants to reassess their initial judgements.
Thus, consensus is reached through a gradual stepwise
process based on rational thinking and input. Second,
the participants do not interact directly and remain
anonymous to each other until the survey rounds end.
Hence, group domination by the views of certain indivi-
duals is avoided. Third, when the participants consider
changing or sticking to their original opinion after
checking group response, this decision is not affected by
the desire to be seen concordant with senior or domin-
ant individuals. Fourth, the experts can participate asyn-
chronously and do not need to be present together
while answering surveys as they receive collective feed-
back along with new surveys, which can be conducted
through a web-based platform. Accordingly, it is feasible
to use this approach to involve geographically distant
participants. Moreover, the controlled feedback mini-
mises the effect of noise, which can happen in face-to-face
group discussions. Finally, the ability to use statistical ana-
lysis facilitates reaching a more objective consensus than
that usually reached through face-to-face conversations.
Consequently, the Delphi method is an appropriate
method to include the knowledge of many experts to
cover the numerous aspects of the medication adher-
ence subject.
AIM
The aim of this Delphi study is to build consensus
among a group of topic experts regarding an item list
that will support developing guidelines for medication
adherence research reporting.
METHODS AND ANALYSIS
Overview of the study design
The study implements a reactive-Delphi design21 where
a group of medication adherence experts will be pro-
vided, in the ﬁrst survey round, with an initial list of 26
items that are speciﬁc to medication adherence
research. They will be asked to rate the relevance and
clarity of the items (on a scale from 1 to 4, where 1 is
the lowest relevance/clarity and 4 is the highest rele-
vance/clarity), with a possibility of suggesting modiﬁca-
tions of the initial items, or new items to be added. After
each round of survey, predeﬁned decision rules will be
applied to keep, delete or modify the items. This
reactive-Delphi design allows for reduction of effort
needed from the experts and faster arrival at consensus
compared with the traditional Delphi design where
experts are asked to come up with all items themselves.
The steering committee
The committee driving this initiative to develop guide-
lines for reporting research on medication adherence
(also the authors of this study protocol) includes
members and founding members of ESPACOMP. One of
their major research interests is medication adherence.
They represent a diversity of disciplines including
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biostatistics, health economics, health policy and man-
agement, health services research, medicine, nursing,
pharmacy, pharmacology, and psychology. Some
members of the committee were involved in develop-
ment of the ABC taxonomy for medication adherence (BV,
DAH and SDG).
Role of the steering committee
The steering committee developed the initial items and
will select the sample of experts for this study. On the
basis of the decision rules, the steering committee will
also apply the corresponding actions after each survey
round: (1) keeping or deleting an item based on rele-
vance scores, and (2) modifying the wording of items
based on clarity scores and the suggestions provided by
the experts. For items that will not have achieved con-
sensus on relevance after the survey rounds will be
stopped, the steering committee will decide on each
item individually based on internal consensus among its
members, taking into consideration the aggregate input
provided by the expert panel. All of the aforementioned
tasks of the steering committee are further detailed later
in this protocol.
Sample and sampling procedures
A purposive sample of medication adherence experts
will be included in the study. The size of the group of
experts needed for participation in any Delphi study
does not depend on statistical power as representative-
ness in such studies is assessed based on the quality of
the sample rather than its size.20 Accordingly, the steer-
ing committee identiﬁed medication adherence experts
based on the representation of disciplines and geo-
graphical locations. In concordance with other similar
projects aiming at developing guidelines for reporting of
health research,16 17 the goal is to include a minimum
of 20 experts in the ﬁnal survey round. To compensate
for possible initial refusal or attrition over rounds, over-
sampling was considered with a rate of 25% per round.
With a literature-based average22 of three rounds until
consensus is achieved, the starting sample will be a
minimum of 40 experts.
More speciﬁcally, the Delphi participants need to be
established experts in the ﬁeld of medication adherence
and satisfy all the following main selection criteria:
1. Having a minimum experience of 5 years in the ﬁeld
of medication adherence;
2. Having an established international proﬁle in this
ﬁeld, recognised by scientiﬁc publications, policy
reports and/or extensive participation in specialised
topic conferences, meetings, or interest groups; and
3. Having good English proﬁciency to complete the
surveys.
To ensure representativeness of all relevant disciplines
and geographical locations, the following variability
selection criteria will be applied:
1. The starting sample will include participants from
each of the following disciplines:
A. Health services research,
B. Clinical research,
C. Statistics,
D. Medicine,
E. Nursing,
F. Pharmacy/pharmaceutical sciences,
G. Pharmaceutical industry,
H. Clinical pharmacology,
I. Pharmacoepidemiology,
J. Behavioural medicine/health psychology,
K. Journal editing,
L. Public health,
M. Health policy;
2. Geographical representation will be ensured by
selecting experts from all continents.
Each of the steering committee members will provide
suggestions for experts to be included on the expert
panel for the Delphi study based on the aforementioned
criteria. Feedback and agreement on the proposed list
by the whole steering committee will be sought before
experts are invited to participate. The ﬁnal choice of the
experts to be included will be based on an optimal distri-
bution and representation of experts in view of the
sample selection criteria (main and variability criteria)
and will be moderated by two members of the steering
committee (SDG and RH). Delphi participants who will
complete all rounds of the study will be listed in the
ﬁnal publication of the reporting guidelines in an
acknowledgement section. However, the study will be
fully anonymised and participants will not be known to
each other during the survey rounds.
Generation of the initial item list
The initial item list was developed and ﬁne-tuned by the
steering committee. First, a literature review was per-
formed to identify existing medication adherence
research guidelines9–11 and recommendations1 12 by two
members of the steering committee (RH and SDG).
This information was summarised and discussed in an
in-person meeting in Prague in November 2015 among
all of the steering committee members. This discussion,
guided by the ABC taxonomy for medication adherence as
well as by a review of common sections of the existing
reporting guidelines for health research reporting (eg,
STROBE, CONSORT), led to the generation of a pool
of items.
Using a stepwise review process, the steering commit-
tee reviewed and further ﬁne-tuned the items in view of
relevance and clarity over four feedback rounds via
email and conference calls. Items were gradually
enhanced and revised to focus exclusively on aspects
relevant to medication adherence. Redundancy between
items of the existing reporting guidelines for health
research (eg, STROBE, CONSORT) and items for
reporting research on medication adherence was scruti-
nised and eliminated where needed.
The resulting initial item list consists of 26 items dis-
tributed in two sections. The ﬁrst section includes four
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items that reﬂect the conceptualisation of medication
adherence as put forward by the ABC taxonomy for medi-
cation adherence and represent the taxonomy-based
minimum reporting criteria. The second section
includes 22 items speciﬁc to medication adherence
research reporting and organised in a way congruent
with common sections of reporting guidelines for major
study types (eg, STROBE, CONSORT).
Decision rules and definition of consensus on relevance
and clarity of items
Since the deﬁnition of consensus varies among Delphi
studies according to the aims of each study, rating scales
along with consensus rules for this study were inspired
by the content validity index23 as it simpliﬁes the
decision-making process as explained below. Square (A)
in ﬁgure 1 shows how the below decision rules will work
together and their possible outcomes.
Item-level decision-making rules
Scores for relevance will be used to decide on keeping or
deleting an item. Consensus on relevance of an item is
deﬁned as 70% of the experts in the sample giving this
item a score of 3 or more on a scale from 1 to 4 (1: not
relevant; 2: somewhat relevant; 3: quite relevant; 4:
highly relevant) during any survey round. Hence, this
item will be kept on the ﬁnal item list. Consensus on
irrelevance of an item is deﬁned as 70% of the respon-
dents giving this item a score of 2 or less during any
survey round. Consequently, this item will be deleted
from the item list.
Scores for clarity of wording will subsequently guide
ﬁne-tuning of the wording of the respective items to be
included on the list. For simplifying the procedures,
only one rule will be used for consensus on lack of
clarity, deﬁned as 70% of the respondents giving this
item a score of 2 or less on a scale from 1 to 4 (1: not
clear; 2: somewhat clear; 3: quite clear; 4: highly clear)
during any survey round. Consensus on lack of clarity
for any item will further lead to using comments pro-
vided by the experts to modify the wording of each cor-
responding item. This will be done by the steering
committee after the rounds end.
List-level decision-making rule
One of the key methodological criteria of Delphi studies
is having a stoppage rule on when the survey rounds will
stop.22 For this purpose, a stoppage rule of having a con-
sensus on relevance for 80% of all items on the list will
be used. In other words, the Delphi rounds will be
stopped once 80% of the items on the list at that point
of time receive consensus on relevance (ie, 80% of the
items received a score ≥3 by 70% of the experts). This
rule will be applied from the ﬁrst round if no new items
will be suggested or from the second round after the
experts will have provided scores for any suggested new
items.
Study procedures
Once the initial item list and the participants’ sample
are ready, the study will start with a preparatory period
of 2 weeks to set up the online environment of the
survey and test its functionality. Afterwards, the survey
rounds will start and continue until the stoppage rule is
fulﬁlled. An invitation for a feedback round will be sent
to the expert group with a response deadline of 2 weeks
after the invitation day. Reminders will be sent to those
who will not respond, or will respond partially. Each
round will be followed by an additional period for sum-
marising and analysing the responses and integrating
the results into the following version of the survey. An
invitation for a next feedback round will be sent out as
described before to the experts who will have completed
all rounds from the beginning until then.
The surveys will be conducted and the responses
will be collected online via a survey platform
(SurveyMonkey). Two members of the steering commit-
tee (SDG and RH) will be responsible for data collection
and responding to possible inquiries from the experts.
In case substantial issues are addressed by any member
of the expert group, the other members of the commit-
tee will be consulted for advice and problem resolution.
A more detailed explanation of the process is provided
below:
1. The ﬁrst survey round will consist of:
A. Providing a score for each of the items in view
of relevance to the topic and clarity of wording;
B. Justifying the scores chosen and/or suggesting
modiﬁcations for each item—(optional—free-
form text);
C. Suggesting additional new items—(optional—
free-form text).
Additionally, the experts will provide information on
their demographics, professional background and spe-
ciﬁc areas of expertise in adherence research for
descriptive purposes as well as conﬁrming their eligibility
in the ﬁrst survey round.
Scores provided for the items will be summarised by
their percentages and frequency distribution and inclu-
sion or deletion of items in the following version of the
survey will be guided by the aforementioned decision
rules. Comments on potential adaptations of item
wording will be summarised and integrated by the steer-
ing committee where deemed relevant.
If no new items will be suggested and consensus on
relevance is reached for 80% of the items on the initial
item list, the survey rounds will be stopped. Otherwise,
the scores and comments of the items that will not have
reached consensus on relevance will be presented in the
following round and/or suggestions of new items will be
summarised and integrated into the following version of
the survey. Further evaluation and decision-making will
follow the methodology described before.
2. The second round: an adapted item list including the
scores and comments of the initial items as well as
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any new items from the ﬁrst round will be sent to the
experts. They will be invited to:
A. Revise their opinion with new relevance and clarity
scores, on the same scale as mentioned before,
and comments for items that will not have achieved
consensus on relevance in the ﬁrst round;
B. Score each of the new items in view of relevance
to the topic and clarity of wording, on the same
scale as mentioned before;
C. Justify the scores chosen and/or suggest modiﬁca-
tions for each item—(optional—free-form text).
If list-level consensus is not reached by the second
round, scores and comments will be summarised as
described in the ﬁrst round and integrated into the item
list to be presented in further rounds until consensus is
reached.
3. Further rounds will consist of presenting consolidated
feedback for all items that will not have achieved con-
sensus on relevance in previous rounds with a chance
for experts to revise their opinion accordingly with:
A. New relevance and clarity scores for the remain-
ing items;
B. Justiﬁcation for the scores chosen and/or modiﬁ-
cations for each item—(optional—free-form text).
Finally, the results of the ﬁnal round will be consoli-
dated and presented to the steering committee for
Figure 1 An overview of the Delphi process.
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proceeding with further steps. The ﬂow chart in ﬁgure 1
delineates the survey rounds based on the input and
output of each round.
ETHICAL AND LEGAL CONSIDERATIONS
Since this study does not use health data of individuals,
ethics approval is not required according to the Swiss
federal act on research involving human beings.
Participants in the Delphi study will be asked to provide
informed consent to have their responses included in
further analysis and dissemination of the results.
Furthermore, they will be informed about conﬁdentiality
of the data and the corresponding legal obligations of
not exposing such data to third parties. Additionally, they
will be asked whether they would like to be acknowledged
in the corresponding publications and dissemination of
the guidelines. All data relevant to the study will be kept
on password-encrypted computers which can be accessed
by the steering committee only.
FURTHER PLANNING OF GUIDELINES DEVELOPMENT
The list of items reached through this study will be inte-
grated by the steering committee into the planned
EMERGE. The guidelines will be disseminated through
peer-reviewed publications, presentations at conferences
of ESPACOMP and other relevant organisations, and
registration of the guidelines with the EQUATOR
network. Endorsement of the guidelines by journals and
relevant professional organisations will be encouraged.
Two members of the steering committee (SDG and RH)
will remain available to receive feedback and criticism
after publication. Accordingly, further updates and revi-
sions of the guidelines will be considered on an annual
basis during ESPACOMP annual meetings, based on the
EQUATOR guidance for developers of health research
reporting guidelines.
OUTLOOK
Medication non-adherence is a public health threat that
causes poor patient outcomes and increased economic
burden.24 25 The quality of medication adherence research
as well as the quality of its reporting will determine the
development and testing of effective and innovative solu-
tions to enhance patients’ adherence to medications and is
therefore of paramount importance to many stakeholders.
EMERGE aims at guiding researchers to report relevant
aspects of medication adherence research in a standard
manner. The use of the guidelines, in combination with
other existing guidelines like STROBE or CONSORT, is
expected to facilitate this task and, subsequently, help
research in the medication adherence ﬁeld advance
towards achieving its ultimate goal of improved outcomes.
DELPHI STUDY STATUS
The initial item list was developed and the online survey
environment was set up and tested by the steering
committee. The sample of experts was chosen and data
collection (ﬁrst round) started in June 2016.
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